Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02721433
Title 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA)
Recruitment Completed
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Ottawa Hospital Research Institute

prostate cancer

breast cancer


Denosumab + pamidronate + Zoledronic acid

Age Groups: adult | senior
Covered Countries CAN

No variant requirements are available.